Nurilign Bulcha, MD
Interventional Cardiology · del Rio, TXNPI 1811309511
Payments from drug & device makers
Across 89 payments — averaging $105.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Abbott$2K
- W. L. Gore & Associates, Inc.$2K
- Edwards Lifesciences$1K
- Inari Medical, Inc.$350
- Abiomed$167
- plus $710 from 11 others
What the payments were for
- Travel & lodging$5,14355%
- Food & beverage$4,08243%
- Education$1922%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 32 | $3,075 |
| Abbott | 12 | $1,929 |
| W. L. Gore & Associates, Inc. | 13 | $1,773 |
| Edwards Lifesciences | 17 | $1,412 |
| Inari Medical, Inc. | 2 | $350 |
| Abiomed | 2 | $167 |
| Cardiovascular Systems Inc. | 1 | $148 |
| Boston Scientific | 1 | $129 |
| Philips North America LLC | 1 | $94 |
| Cathworks, Inc. | 1 | $84 |
| Chiesi USA, Inc. | 1 | $79 |
| Penumbra, Inc. | 1 | $63 |
| Bayer | 1 | $26 |
| Amgen | 1 | $25 |
| Lilly USA, LLC | 1 | $22 |
| Teleflex LLC | 1 | $22 |
| Scpharmaceuticals Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PERCLOSE PROGLIDE$1,408
- GORE CARDIOFORM Septal Occluder$1,351
- TurboHawk$1,302
- COREVALVE EVOLUT R$830
- Edwards SAPIEN 3 Transcatheter Heart Valve$460
- FLOWTRIEVER CATHETER, S$350
- CT THROMBECTOMY SYSTEM KIT$350
- Diamondback Coronary$148
- Impella$142
- WOLVERINE CORONARY CUTTING BALLOON$129
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$109
- MitraClip$101
How this compares
$9,417 in reported general payments places this provider in the 45th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 41 | $43,445 |
| EntrestoSacubitril/Valsartan | 19 | $25,042 |
| Metoprolol Succinate | 91 | $1,154 |
| Rosuvastatin Calcium | 30 | $631 |
| Potassium Chloride | 26 | $450 |
| Atorvastatin Calcium | 58 | $417 |
| Digoxin | 12 | $289 |
| Losartan Potassium | 30 | $274 |
| ClopidogrelClopidogrel Bisulfate | 16 | $245 |
| Ezetimibe | 18 | $180 |
| Carvedilol | 27 | $179 |
| Amlodipine Besylate | 41 | $146 |
| Lisinopril | 14 | $94 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 12 | $80 |
| Furosemide | 17 | $74 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in del Rio
- Robert StolerDallas$8.2M
- James ChoiDallas$5.2M
- Srinivasa PotluriPlano$5.1M
- Neal KleimanHouston$4.8M
- Juan GranadaHouston$4.3M
- Ira LieberKingwood$3.3M
- Cara Ann EastDallas$3M
- Abhijeet DhobleHouston$2.7M
- Jeffrey CarrTyler$2.7M
- M Asad KarimMcKinney$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.